On today’s Stop Trading segment on CNBC, Jim Cramer said he was shocked that Revlimid from Celgene (CELG) was hardly noticed and he thinks it’s ready to run here. This down move in Celgene is a mistake. He’s sticking with his Onyx Pharmaceuticals Inc. (ONXX) after they gave positive data at the American Society of Clinical Onclogy ("ASCO") after the company extended the life of liver cancer patients.
Cramer said he’d still buy Wal-Mart (WMT-NYSE) here even after the run from the news Friday and after the upgrades today.
Jon C. Ogg
June 4, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
